medigraphic.com
Academia Mexicana de Neurología, A.C.

2007, Number 1

<< Back Next >>

Rev Mex Neuroci 2007; 8 (1)

Phase II study for the treatment of relapsing-remitting multiple sclerosis patients with biomoduline T

Gámez MLA, Lara RRF, Rodríguez MR, González-Quevedo MA, Fernández CR, Marzoa SN

Language: Spanish
References: 19
Page: 28-31
PDF size: 363.85 Kb.


ABSTRACT

Introduction: Multiple sclerosis (MS) continues being a neurological entity of unknown etiology. In the present work we show the results obtained with the use of parentheral and biomoduline T (BT), a Cuban bovine thymic extract, with immunomodulatory and anti-inflammatory effects. Patients and methods: Two groups of patients with clinically defined relapsing-remitting MS were treated with BT: group 1 with parentheral BT and group 2 with oral steroids and intramuscular Vitamin B12 for 3 years. In both groups the number of exacerbations 2 years before treatment and at conclusion of therapy was evaluated. Results: After 3 years of treatment, a 68 and 48% reduction of exacerbations were observed in groups 1 and 2, as well as stability of EDSS in 88 and 68% of patients, and a decrease of the IgG Index. Conclusions: BT had similar beneficial effects in MS patients treated with BT and steroids, and could be a possible therapy for MS, alone or combined with other drugs.


REFERENCES

  1. Rovira Cañellas A, Alonso Farré J, Río Izquierdo J. Resonancia magnética en el seguimiento clínico y terapéutico de la esclerosis múltiple. Rev Neurol 2000; 30: 980-5.

  2. Bender J, Hernández E, Barnes J, León M, Concepción B. Concepción bioética, restauración neurológica y esclerosis múltiple. Rev Mexicana de Neurociencia 2002; (1): 25-32.

  3. Arnason BGW. Interferon beta in MS. Neurology 1993; 43: 641-3.

  4. Johnson KP, Bross RR, Cohen JA, Ford CC Goldstein, Lisak RP, et al. Copolymer 1 reduce relapse rate and improves disability in R.R. MS, results of phase III multicenter double blind placebo controlled trial. Neurology 1995; 45: 1268-76.

  5. Documentación para el registro del medicamento biomodulina T inyección IM, IV No registro 0722 Dic. 1994, CECMED, Cuba.

  6. Trainin N, Pecht M, Handzel ZT. Thymic hormones inducers and regulators of T cell system. Elsevier Biomedical Press 1983; l4: 36-41.

  7. Handzel ZT, Burstein Y, Bucher V, Precht M, Trainin N. Inmunomodulation of T cell deficiency in humans by thymic hum oral factor from crude extract of synthetic hum oral factor gamma 2. J Biological Response Modifiers 1990; 9: 269- 78.

  8. Sigarroa Medina F, Vallejo Patton V. Relación entre las propiedades inmunomoduladoras de la biomodulina T. Tesis de Diploma. Instituto de Farmacia y Alimentos (IFAL), Universidad de La Habana, 1995.

  9. Gamez L, González Quevedo A, Alfaro I, Rodríguez R. Estudio clínico terapéutico en pacientes con EM de forma E-R tratados con biomodulina T. Memorias del II Congreso Internacional de Turismo de Salud May/1996. Publicación por soporte magnético. Academia de Ciencias de Cuba.

  10. León Cofiño L. Estudio de la acción antiinflamatoria de la biomodulina T. Tesis de Diploma. Instituto de Farmacia y Alimentos, Universidad de la Habana, 1995.

  11. Lara Rodríguez RF, Gamez Morales L, Rodríguez R, Paz Sendín L, Vargas A, Viada González C, et al. Multicenter clinical trial: Treatment of the exacerbation of multiple sclerosis with biomodulina T (1998-2003), clinical efficacy. Arquivos de Neuro-psiquiatría. Jornal Oficial da Academia Brasileira de Neurología 2004; 62(Suppl. 1): 36.

  12. Prieto JM, Lema M. Interferón beta en la esclerosis múltiple. Rev Neurol 2003; 36: 980-90.

  13. Miller DH. The role of MRI in diagnosis and treatment of MS. MS Management 1995; 2-1: 36-42.

  14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.

  15. Tibling G, Link H, Ohman S. Principles of albumin IgG analysis. Neurological disorders. I. Establishment of reference. Scand J Clin Lab Invest 1977; 37: 385-90.

  16. Tourtellotte WW, Syndulko K, Baumhefner RW, Shapshak P, Osborne MA. Comprehensive protocol for clinical trial in MS which favoured azathioprine and corticosteroid as type of treatment for chronic progressive phase. Neurology 1988; 38(Suppl.): 83-5.

  17. Martínez Sobrepera, Cabrera Gómez JA, Tuero Iglesias A. Factores exógenos en la etiología de la esclerosis múltiple en Cuba. Estudio de casos y controles. Rev Neurol 2001; 33(10): 928-30.

  18. Kremenschuztky M. La historia natural de la Esclerosis Múltiple. Rev Neurol 2000; 30: 967-72.

  19. Ramo Tello C, León –Colombo T. ¿Qué tratamiento debemos emplear actualmente en la esclerosis múltiple? Rev Neurol 2000; 30: 993-5.




2020     |     www.medigraphic.com